Literature DB >> 28256427

Midterm Effect of Balloon Pulmonary Angioplasty on Hemodynamics and Subclinical Myocardial Damage in Chronic Thromboembolic Pulmonary Hypertension.

Mai Kimura1, Takashi Kohno2, Takashi Kawakami1, Masaharu Kataoka1, Toshimitsu Tsugu1, Keitaro Akita1, Sarasa Isobe1, Yuji Itabashi1, Yuichiro Maekawa1, Mitsushige Murata1, Keiichi Fukuda1.   

Abstract

BACKGROUND: The acute favourable effect of balloon pulmonary angioplasty (BPA) has been proven in patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, data on its effect 6 months after therapy (from now on referred to as mid-term) and influence on the right ventricle and myocardial damage are sparse. To evaluate factors that influence improvement in cardiac output (CO) and subclinical myocardial damage, we examined hemodynamics and serum high-sensitivity troponin T (hs-TnT) levels before, 1 week after, and 6 months after BPA.
METHODS: In a retrospective study, we reviewed 67 consecutive patients from November 2012 to January 2016 with CTEPH who had undergone BPA at Keio University Hospital.
RESULTS: Six months after BPA, the mean right atrium pressure, mean pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), B-type natriuretic peptide (BNP), and hs-TnT levels decreased; CO and 6-minute walking distance increased. Changes in CO and hs-TnT levels varied compared with other hemodynamic parameters and BNP levels. The CO-increase group (n = 42) had higher mean PAP and PVR, and lower CO at baseline than the CO-decrease/stable group (n = 25). The hs-TnT-decrease group (n = 36) had higher mean right atrium pressure, PAP, PVR, and BNP levels, and lower CO at baseline than the hs-TnT-increase/stable group (n = 31).
CONCLUSIONS: Six months after BPA, hemodynamics and exercise capacity improved and hs-TnT levels decreased. Improvements in CO and hs-TnT levels were more prominent in CTEPH patients with impaired baseline hemodynamics, suggesting that BPA has a favourable mid-term effect on hemodynamics and subclinical myocardial damage in patients with CTEPH, especially in those with impaired hemodynamics.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28256427     DOI: 10.1016/j.cjca.2016.12.003

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

Review 1.  Balloon Pulmonary Angioplasty as a Treatment in Chronic Thromboembolic Pulmonary Hypertension: Past, Present, and Future.

Authors:  Panagiotis Karyofyllis; Eftychia Demerouti; Varvara Papadopoulou; Vassilis Voudris; Hiromi Matsubara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-02-13

Review 2.  Balloon Pulmonary Angioplasty in Patients With Thromboembolic Pulmonary Hypertension.

Authors:  Panagiotis Karyofyllis; Varvara Papadopoulou; Vassilis Voudris; Hiromi Matsubara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-24

3.  Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study.

Authors:  Takashi Kawakami; Hiromi Matsubara; Kohtaro Abe; Masaharu Kataoka; Shun Kohsaka; Yasunori Sato; Toshiro Shinke; Keiichi Fukuda
Journal:  BMJ Open       Date:  2020-02-06       Impact factor: 2.692

4.  Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Authors:  Steffen D Kriechbaum; Christoph B Wiedenroth; Till Keller; Jan Sebastian Wolter; Ruth Ajnwojner; Karina Peters; Moritz A Haas; Fritz C Roller; Andreas Breithecker; Andreas J Rieth; Stefan Guth; Andreas Rolf; Dirk Bandorski; Christian W Hamm; Eckhard Mayer; Christoph Liebetrau
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

5.  Regional Right Ventricular Abnormalities Implicate Distinct Pathophysiological Conditions in Patients With Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Hidenori Moriyama; Takashi Kawakami; Masaharu Kataoka; Takahiro Hiraide; Mai Kimura; Jin Endo; Takashi Kohno; Yuji Itabashi; Yoshihiro Seo; Keiichi Fukuda; Mitsushige Murata
Journal:  J Am Heart Assoc       Date:  2020-10-27       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.